Prelude Capital Management’s AtriCure ATRC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $242K | Buy |
+8,639
| New | +$243K | 0.02% | 890 |
|
|
2026
Q1 | – | Sell |
-6,095
| Closed | -$241K | – | 1215 |
|
|
2025
Q4 | $241K | Buy |
+6,095
| New | +$223K | 0.02% | 920 |
|
|
2024
Q2 | – | Sell |
-7,143
| Closed | -$217K | – | 1217 |
|
|
2024
Q1 | $217K | Sell |
7,143
-25,321
| -78% | -$848K | 0.01% | 1069 |
|
|
2023
Q4 | $1.16M | Buy |
32,464
+20,738
| +177% | +$771K | 0.08% | 268 |
|
|
2023
Q3 | $514K | Buy |
11,726
+3,767
| +47% | +$184K | 0.03% | 470 |
|
|
2023
Q2 | $393K | Buy |
+7,959
| New | +$367K | 0.03% | 560 |
|
|
2023
Q1 | – | Sell |
-12,362
| Closed | -$549K | – | 1175 |
|
|
2022
Q4 | $549K | Buy |
12,362
+5,161
| +72% | +$216K | 0.03% | 534 |
|
|
2022
Q3 | $282K | Sell |
7,201
-508
| -7% | -$23.2K | 0.01% | 896 |
|
|
2022
Q2 | $315K | Buy |
+7,709
| New | +$365K | 0.01% | 1036 |
|
|
2022
Q1 | – | Sell |
-3,290
| Closed | -$229K | – | 1809 |
|
|
2021
Q4 | $229K | Buy |
3,290
+235
| +8% | +$17.1K | 0.01% | 1488 |
|
|
2021
Q3 | $212K | Sell |
3,055
-1,030
| -25% | -$79.3K | 0.01% | 1333 |
|
|
2021
Q2 | $324K | Buy |
+4,085
| New | +$297K | 0.01% | 1160 |
|
|
2020
Q1 | – | Sell |
-39
| Closed | -$1K | – | 1432 |
|
|
2019
Q4 | $1K | Sell |
39
-1,315
| -97% | -$37.4K | ﹤0.01% | 1843 |
|
|
2019
Q3 | $34K | Buy |
1,354
+733
| +118% | +$20.9K | ﹤0.01% | 1275 |
|
|
2019
Q2 | $19K | Sell |
621
-1,621
| -72% | -$47.3K | ﹤0.01% | 1291 |
|
|
2019
Q1 | $60K | Buy |
2,242
+1,785
| +391% | +$54.2K | ﹤0.01% | 1074 |
|
|
2018
Q4 | $14K | Buy |
457
+235
| +106% | +$7.32K | ﹤0.01% | 1296 |
|
|
2018
Q3 | $8K | Buy |
222
+14
| +7% | +$443 | ﹤0.01% | 1502 |
|
|
2018
Q2 | $6K | Sell |
208
-19,930
| -99% | -$468K | ﹤0.01% | 1542 |
|
|
2018
Q1 | $413K | Buy |
20,138
+1,086
| +6% | +$19.6K | 0.03% | 491 |
|
|
2017
Q4 | $348K | Buy |
19,052
+4,840
| +34% | +$95.8K | 0.03% | 505 |
|
|
2017
Q3 | $318K | Buy |
14,212
+365
| +3% | +$8.25K | 0.03% | 502 |
|
|
2017
Q2 | $336K | Buy |
13,847
+3,233
| +30% | +$68.7K | 0.03% | 427 |
|
|
2017
Q1 | $203K | Sell |
10,614
-6,528
| -38% | -$114K | 0.02% | 554 |
|
|
2016
Q4 | $335K | Buy |
17,142
+15,038
| +715% | +$273K | 0.04% | 405 |
|
|
2016
Q3 | $33K | Buy |
+2,104
| New | +$32.3K | ﹤0.01% | 1183 |
|
|
2015
Q2 | – | Sell |
-3,000
| Closed | -$61K | – | 1685 |
|
|
2015
Q1 | $61K | Buy |
+3,000
| New | +$58.1K | 0.01% | 1204 |
|
Other funds holding ATRC
Prelude Capital Management's ATRC Position: Q2 2026 in Review
Prelude Capital Management opened a new position in AtriCure (ATRC) in Q2 2026: 8,639 shares worth $242K. The stake represents 0.02% of the portfolio and ranks #890 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in ATRC as recently as Q4 2025.
Prelude Capital Management first reported a position in ATRC in Q1 2015 and has held it in 27 quarters since. The position peaked at $1.16M in Q4 2023. 251 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.
- Prelude Capital Management held 8,639 shares of AtriCure worth $242K as of Q2 2026.
- AtriCure was a new Prelude Capital Management position in Q2 2026.
- AtriCure made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #890 holding.
- Prelude Capital Management first reported a position in AtriCure in Q1 2015 and has held it in 27 quarters since.
- Prelude Capital Management's AtriCure position peaked at $1.16M in Q4 2023.
- 251 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.